Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (June and 1st Half of 2017)

Thursday, July 20, 2017

Between January and June 2017, Russia imported 5,600 tons of active pharmaceutical ingredients (API), worth 35.7 bln RUB (free circulation prices). In monetary terms, it is 30% higher than that of the same period of 2016. In physical terms, the dynamics is 7%.

China is the absolute leader in the API import, with 20% of the import in monetary terms, which is, however, 6% lower than that of the same period of 2016. In physical terms though, China imported 69% of all the API import to Russia, with 333 API names. French manufacturers come second, with 16.6% of the import, which is in monetary terms 9% higher than that of the same period of 2016.

Ireland has the biggest growth rates, with the import having risen by nearly 400 times. Pneumococcal monovalent polysaccharide conjugates (antigens for vaccine production for the prevention of pneumococcal infections by Pfizer) account for most of the import. Antigens account for most of the total import volume (5.8%).

Read more about API import to Russia (December 2016 and Yearly Performance) here:

Tab 1. Top 15 API names with the largest import to Russia (Q1 – Q2 2017), in monetary terms